| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3487 | Mrs4608 | Novel potent antagonist of P2Y 14 receptor (P2Y 14 R) (IC 50 ~20 nM at hP2Y 14 R/mP2Y 14 R) |
|
| DCC3488 | Mrs4654 | Novel potent P2Y14 Receptor Antagonist (IC 50 , 15 nM) |
|
| DCC3489 | Mrs7396 | Bitopic fluorescent antagonist of the A2A adenosine receptor |
|
| DCC3490 | Mrs7469 | Novel highly selective A1 adenosine receptor (A1AR) agonist |
|
| DCC3491 | Mrs7591 | Novel Partial Agonist of Human and Mouse A3 Adenosine Receptors (Ki = 10.9/17.8 nM, at human/mouse A3AR) |
|
| DCC3492 | Mrs7799 | Novel highly potent A3 adenosine receptor (A3AR) antagonist with Kd values (nM): 0.55 (human), 3.74 (mouse), and 2.80 (rat) |
|
| DCC3493 | Mrt-68601 Hydrochloride | Potent inhibitor of TANK-binding kinase-1 (TBK1)/IKKepislon kinases |
|
| DCC3494 | Mrt-92 Hydrochloride | Novel inhibitor of Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor |
|
| DCC3495 | Mrz-8676 | Novel, selective, orally bioavailable, negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5) |
|
| DCC3496 | ms0017509 | Inhibitor of DNA damage repair |
|
| DCC3497 | ms0019266 | Novel inhibitor of DNA damage repair |
|
| DCC3498 | Ms2126 | Novel inhibitor of Human p53 and CREB Binding Protein (CREBBP) interaction |
|
| DCC3499 | Ms2177 | Novel potent and selective SETD8 inhibitor |
|
| DCC3500 | Ms2i6a | Mitochondrial tRNA-specific modification, regulating efficient mitochondrial translation and energy metabolism in mammals |
|
| DCC3501 | Msc2524070 | Novel potent tankyrase (TNKS) inhibitor (EC 50 : 2 nM) |
|
| DCC3502 | Msc-4381 | Novel inhibitor of SLC16A3 |
|
| DCC3503 | Msd-496486311 | Novel potent and selective PI3Kδ inhibitor |
|
| DCC3504 | Msk-195 | Potent TRPV1 agonist |
|
| DCC3505 | Mßl-in-2i | Novel potent broad-spectrum metallo-β-lactamase (MβL) inhibitor, inhibiting the MβLs NDM-1, VIM-2, ImiS, and L1 |
|
| DCC3506 | Mt1/2 Agonist (s)-3b | Novel BBB permeable potent MT1 and MT2 ligand (MT1, Ki = 0.031 nM; MT2, Ki = 0.070 nM) with good metabolic stability in human hepatic microsomes |
|
| DCC3507 | Mtc420 | Novel antituberculosis agent. targeting the respiratory chain of Mycobacterium tuberculosis (Mtb) and being effective against multi drug resistant (MDR) Mtb |
|
| DCC3508 | Mtd12813 | Novel minimized theta-defensin, being highly effective against CRE pathogens K. pneumoniae and E. coli in vivo, significantly enhancing survival by promoting rapid host-mediated bacterial clearance and by modulating pathologic cytokine responses, restorin |
|
| DCC3509 | Mtdl-4e | Novel resveratrol-based multitarget-directed ligand, cellularly activating the NRF2-ARE pathway (CD = 9.83 μM), selectively inhibiting both hMAO-B and QR2 (IC 50 s = 8.05 and 0.57 μM), and promoting hippocampal neurogenesis |
|
| DCC3510 | Mthp Hydrobromide | Selective antagonist of melanocortin-4 receptor (MC4R) |
|
| DCC3511 | Mtmox32e | Novel Mithramycin A (MTM) 2'-oxime (MTMox) conjugate, displaying an 11-fold increase in plasma exposure and improved efficacy in an Ewing sarcoma xenograft |
|
| DCC3512 | Mtor Inhibitor-7 | Novel, potent, and selective brain-penetrant ATP-competitive mTOR inhibitor |
|
| DCC3513 | Mtor/hdac1-in-12l | Novel potent dual inhibitor of mTOR and HDAC1 |
|
| DCC3514 | Mtorc1-in-1 | Novel selective inhibitor of mTORC1, yielding potent inhibition of glucose uptake |
|
| DCC3515 | Mtorc1-in-i | Novel selective mTORC1 inhibitor, directly targeting class I glucose transporters |
|
| DCC3516 | Mtor-in-17 | Novel mTOR inhibitor, exhibiting potent anticancer activities against four tumor cell lines, including MCF-7, HeLa, MGC-803, and C6, inducing cell death via apoptosis by targeting both mTORC1 and mTORC2 within cells and arrests the cell cycle of HeLa at t |
|
